EXOZ
What one share of Exozymes holds
Biological Products, (No Diagnostic Substances)
Exozymes’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.20 |
|---|---|
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$0.84 |
| Cash and investments | $0.61 |
| Book value | $0.39 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $0.01 | −$0.33 | $0.05 | −$0.24 | — | −$0.06 |
| 2024 | — | −$0.89 | $0.06 | −$1.36 | — | $1.25 |
| 2025 | — | −$1.09 | $0.02 | −$0.80 | — | $0.40 |